Zanubrutinib is a novel selective covalent inhibitor of BTK with limited activity against alternative targets versus ibrutinib [31], and it demonstrated activity in early phase clinical trials in B-cell lymphomas including CLL and SLL. Here, BTK is linked to B-cell chronic lymphocytic leukemia.